Glaxo fires some China staff for malpractice amid stepped-up surveillance

With GlaxoSmithKline's ($GSK) China operations under investigation amid bribery allegations, the company is keeping its employees there under a more watchful eye. As Reuters reports, that extra surveillance helped turn up failures to comply with expense rules, leading to the firing of some staffers for malpractice. "Where we have found potential issues, we are thoroughly reviewing them and have withheld incentive payments where appropriate," a Glaxo spokesman told the news service. More

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.